Exosome Diagnostics, Eli Lilly Partner on Biomarker Discovery | GenomeWeb

NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has entered into a collaboration agreement with Eli Lilly for biomarker discovery and validation using Exosome's EXO50 nucleic acid extraction kit.

Under the agreement, the financial terms of which were not disclosed, Lilly will gain early access to Exosome's technology to help it identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?